On April 15, GLONGHUI Bio-B (02157.HK) announced the latest status of the exclusive global license agreement between KYM Biosciences Inc. (“KYM”, a joint venture formed by the company and Connoya Biomedical Technology Co., Ltd. (“Connoya”) and AstraZeneca AB (“AstraZeneca”, a global pharmaceutical company) to develop and commercialize CMG901 (a drug candidate jointly developed by the company and Connoya through KYM).

In February 2023, KYM signed a license agreement with AstraZeneca to develop and commercialize CMG901. After signing the license agreement and obtaining certain regulatory approvals in connection with the licensing transaction, AstraZeneca was granted an exclusive global license to research, develop, register, produce and commercialize CMG901 in February 2023, and is responsible for all costs and activities associated with its further development and commercialization in accordance with the license agreement.

As of the date of this announcement, AstraZeneca has conducted a number of clinical studies on CMG901 in the treatment of advanced solid tumors. An international multicenter phase III study comparing CMG901 monotherapy with the researchers' selected regimen as second-line or higher treatment in advanced or metastatic gastric and gastroesophageal adenocarcinoma patients expressing Claudin 18.2 was announced on the Drug Clinical Trial Registration and Information Platform in March 2024. The first patient completed the first dose on April 11, 2024.